RGD Reference Report - Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.

Authors: Yokoyama, Takuhei  Enomoto, Takayuki  Serada, Satoshi  Morimoto, Akiko  Matsuzaki, Shinya  Ueda, Yutaka  Yoshino, Kiyoshi  Fujita, Masami  Kyo, Satoru  Iwahori, Kota  Fujimoto, Minoru  Kimura, Tadashi  Naka, Tetsuji 
Citation: Yokoyama T, etal., Int J Cancer. 2013 Jan 15;132(2):472-84. doi: 10.1002/ijc.27679. Epub 2012 Jul 9.
RGD ID: 14398498
Pubmed: PMID:22729361   (View Abstract at PubMed)
DOI: DOI:10.1002/ijc.27679   (Journal Full-text)

This report utilizes a novel proteomic method for discovering potential therapeutic targets in endometrial cancer. We used a biotinylation-based approach for cell-surface protein enrichment combined with isobaric tags for relative and absolute quantitation (iTRAQ) technology using nano liquid chromatography-tandem mass spectrometry analysis to identify specifically overexpressed proteins in endometrial cancer cells compared with normal endometrial cells. We identified a total of 272 proteins, including 11 plasma membrane proteins, whose expression increased more than twofold in at least four of seven endometrial cancer cell lines compared with a normal endometrial cell line. Overexpression of bone marrow stromal antigen 2 (BST2) was detected and the observation was supported by immunohistochemical analysis using clinical samples. The expression of BST2 was more characteristic of 118 endometrial cancer tissues compared with 59 normal endometrial tissues (p < 0.0001). The therapeutic effect of an anti-BST2 antibody was studied both in vitro and in vivo. An anti-BST2 monoclonal antibody showed in vitro cytotoxicity in BST2-positive endometrial cancer cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. In an in vivo xenograft model, anti-BST2 antibody treatment significantly inhibited tumor growth of BST2-positive endometrial cancer cells in an NK cell-dependent manner. The anti-BST2 antibody had a potent antitumor effect against endometrial cancer both in vitro and in vivo, indicating a strong potential for clinical use of anti-BST2 antibody for endometrial cancer treatment. The combination of biotinylation-based enrichment of cell-surface proteins and iTRAQ analysis should be a useful screening method for future discovery of potential therapeutic targets.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
BST2Humanendometrial cancer treatmentIMP  RGD 
BST2Humanendometrial cancer  IEP protein:increased expression:endometrium:RGD 
Bst2Ratendometrial cancer treatmentISOBST2 (Homo sapiens) RGD 
Bst2Ratendometrial cancer  ISOBST2 (Homo sapiens)protein:increased expression:endometrium:RGD 
Bst2Mouseendometrial cancer treatmentISOBST2 (Homo sapiens) RGD 
Bst2Mouseendometrial cancer  ISOBST2 (Homo sapiens)protein:increased expression:endometrium:RGD 

Objects Annotated

Genes (Rattus norvegicus)
Bst2  (bone marrow stromal cell antigen 2)

Genes (Mus musculus)
Bst2  (bone marrow stromal cell antigen 2)

Genes (Homo sapiens)
BST2  (bone marrow stromal cell antigen 2)


Additional Information